ArticleQuantitative imaging in medicine and surgery2025
Cardiac involvement in patients with anti-MDA5 Ab+ dermatomyositis: a cross-sectional study with cardiac magnetic resonance.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anti-MDA5 antibody-positive dermatomyositis (anti-MDA5 Ab+ DM) is increasingly recognized to involve the heart, yet the prevalence and phenotype of cardiac involvement remain insufficiently characterized. This study aimed to determine the utility of cardiac magnetic resonance (CMR) for detecting myocardial involvement (MI) in patients with anti-MDA5+ DM. Methods: We prospectively included 42 anti-MDA5+ DM patients (male: 23, median age: 45 years) and 29 age- and gender-matched healthy controls (HCs). All participants underwent CMR to evaluate left ventricular function, native T1 and T2 value, and late gadolinium enhancement (LGE). Results: Patients with anti-MDA5+ DM exhibited significantly reduced left ventricular ejection fraction (LVEF) compared to HCs (P<0.001). They also had elevated myocardial T1 (P<0.001) and T2 (P<0.001) values. LGE was detected in 35.7% of patients. Compared to the LGE-negative group, patients with LGE-positive findings had higher creatine kinase myocardial band (CK-MB) levels (P<0.001) and lower cardiac index (CI, P<0.05). We stratified anti-MDA5+ DM patients into subgroups according to predefined thresholds for the biomarkers. The inflammatory marker-positive subgroup showed significantly increased left ventricular end-diastolic volume index (LVEDVI) and reduced CI compared to the negative subgroup (LVEDVI: 64.0±17.1 Conclusions: Left ventricular involvement is highly prevalent in anti-MDA5+ DM patients, as evidenced by CMR. The study reinforces CMR as a valuable diagnostic tool for MI in anti-MDA5+ DM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.